Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2

Abstract

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , W 1 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b , and R 10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

1 - 20 . (canceled) 
     
     
         21 . A compound according to Formula (I): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof wherein:
 A 1  is —CR 6a ; 
 A 2  is —N— or —CR 6a ; 
 A 3  is —N— or —CR 7 ; 
 A 4  is —N— or —CR 6b ; 
 A 5  is —NR 8  or —CR 8a R 8b ; 
 W 1  is O, S, NH, NO(R 9 ) or CR 9a R 9b ; 
 Y is —O—, —S—, —C(O)—, —NR 10 , —S═O, —S(O) 2 —, —CH 2 — or —CH(OH); 
 n is 1, 2 or 3; 
 R 1  and R 2  independently are —H, —NHR 10 , NHR 10 -alkylene, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, cycloalkyl, heterocyclyl, heteroaryl, aryl, arylalkylene, cycloalkylalkylene, heterocyclylalkylene, or heteroarylalkylene, such that at least one of R 1  or R 2  is not —H; or 
 R 1  and R 2  together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl ring; 
 R 3 , R 4 , R 5  and R 6b  independently are —H, —OH, —CN, —SR 10 , halogen, —S(O) 2 (C 1 -C 8 ) alkyl, —C(O)NHR 10 , —C(O)NR 10 R 10 , —NHR 10 , —NR 10 R 10 , NHR 10 -alkylene, NR 10 R 10 -alkylene, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )haloalkyl, —O(C 1 -C 8 )alkyl, —O(C 1 -C 8 )haloalkyl, —O(C 1 -C 8 )alkyleneNHR 10 , —O(C 1 -C 8 )alkyleneNR 10 R 10 , cycloalkyl, heterocyclyl, heteroaryl, aryl, arylalkylene, cycloalkylalkylene, heterocyclylalkylene, heteroarylalkylene, alkylaminyl, alkylcarbonylaminyl, cycloalkylcarbonylaminyl, cycloalkylaminyl, or heterocyclylaminyl; or 
 R 4  and R 5  together with the respective carbon atoms to which they are attached form a fused aryl, cycloalkyl, heterocyclyl or heteroaryl ring; 
 R 6a  is —H, —OH, halogen, —CN, acetyl, —(C 1 -C 8 )alkyl, —S(C 1 -C 8 )alkyl, —(C 2 -C 8 )alkenyl, —(C 2 -C 8 )alkynyl, —O(C 1 -C 8 )alkyl, —(C 1 -C 8 )haloalkyl, —NHR 10 , —NR 10 R 10 , NHR 10 -alkylene, NR 10 R 10 -alkylene or —O(C 1 -C 8 )haloalkyl; 
 R 7  is —H, —OH, —SH, —CN, —S(O) 2 R 10 , halogen, —S(C 1 -C 8 )alkyl, —NHR 10 , —NR 10 R 10 , (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )haloalkyl, —O(C 1 -C 8 )haloalkyl, —O(C 1 -C 8 )alkyl, —O(C 1 -C 8 )alkyleneNHR 10 , —O(C 1 -C 8 )alkyleneNR 10 R 10 , —(C 1 -C 8 )alkyleneNHR 10 , —(C 1 -C 8 )alkyleneNR 10 R 10 , —S(C 1 -C 8 )alkyl, cycloalkyl, heterocyclyl, heteroaryl or aryl; 
 R 8  is —H, —OH, acetyl, —(C 1 -C 8 )alkyl, —C(O)alkyl, —C(O)cycloalkyl, —C(O)O—(C 1 -C 8 )alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 
 R 8a  and R 8b  independently are —H, —OH, acetyl, —(C 1 -C 8 )alkyl, —O(C 1 -C 8 )alkyl, —C(O)alkyl, —C(O)cycloalkyl, —C(O)O—(C 1 -C 8 )alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 
 R 9 , R 9a  and R 9b  are independently —H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, cycloalkyl, heterocyclyl, heteroaryl, aryl, arylalkylene, cycloalkylalkylene, heterocyclylalkylene, or heteroarylalkylene; or 
 R 9a  and R 9b  together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl ring; 
 R 10  is —H, —OH, —C(O)O(C 1 -C 8 )alkyl, —C(O)(C 1 -C 8 )alkyl, —C(O)—NH 2 , —C(O)—NH(C 1 -C 8 )alkyl, NH 2 —C(O)-alkylene, —S(C 1 -C 8 )alkyl, acetyl, —(C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, —O(C 1 -C 8 )alkyl, (C 1 -C 8 ) haloalkyl, alkylcarbonylaminyl, alkylaminyl, —C(O)alkyl, —C(O)cycloalkyl, —C(O)O—(C 1 -C 8 )alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; 
 wherein any alkyl, cycloalkyl, heterocyclyl, heteroaryl, aryl, arylalkylene, cycloalkylalkylene, heterocyclylalkylene, heteroarylalkylene, alkylaminyl, alkylcarbonylaminyl, cycloalkylcarbonylaminyl, cycloalkylaminyl, or heterocyclylaminyl is optionally substituted with 1, 2, or 3 groups selected from —OH, —CN, —SH, —S(O)NH 2 , —S(O)NH 2 , halogen, —NH 2 , —NH(C 1 -C 4 )alkyl, —N[(C 1 -C 4 )alkyl] 2 , —C(O)NH 2 , —COOH, —COOMe, acetyl, —(C 1 -C 8 )alkyl, —O(C 1 -C 8 )alkyl (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, haloalkyl, thioalkyl, cyanomethylene, alkylaminyl, NH 2 —C(O)-alkylene, NH 2 —C(O)-alkylene, —NH(Me)-C(O)-alkylene, —CH 2 —C(O)-lower alkyl, —C(O)-lower alkyl, alkylcarbonylaminyl, cycloalkyl, cycloalkylalkylene, cycloalkylalkenylene, cycloalkylcarbonylaminyl, cycloalkylaminyl, —CH 2 —C(O)-cycloalkyl, —C(O)-cycloalkyl, —CH 2 —C(O)-aryl, —CH 2 -aryl, —C(O)-aryl, —CH 2 —C(O)-heterocycloalkyl, —C(O)-heterocycloalkyl, heterocyclylaminyl or heterocyclyl. 
 
     
     
         22 . The compound according to  claim 21 , wherein W 1  is O, A 5  is —NR 8  and R 8  is —H. 
     
     
         23 . The compound according to  claim 21 , wherein Y is —NR 10  and subscript “n” is 1. 
     
     
         24 . The compound according to  claim 23 , wherein R 10  is —H or —(C 1 -C 8 )alkyl. 
     
     
         25 . The compound according to  claim 21 , wherein at least one of R 1  or R 2  is methyl, ethyl, i-propyl, —NH 2 , aminomethylene, CH 3 —OC(O)NH-methylene or thiophene. 
     
     
         26 . The compound according to  claim 21 , wherein R 1  and R 2  together with the carbon atom to which they are attached form a cycloalkyl ring selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, 2,2-dimethylcyclobutyl, 4-aminocyclohexyl, 4-methylcyclohexyl, 4-ethylcyclohexyl, 2,2-difluoroethyl-4-cyclohexyl, 4,4-difluorocyclohexy, 4-cyanocyclohexyl, 4-trifluoromethylcyclohexyl, 4-hydroxycyclohexyl, 3-hydroxycyclopently, 3-aminocyclopentyl and 3-methylcyclopentyl. 
     
     
         27 . The compound according to  claim 21 , wherein A 2  is —CH, A 4  is —CR 6b  and —CR 6b  is —C(OH), —C(CN), —C(F), —C(Cl), —C(OMe), —C(Me), —C(Et), —C(CF 3 ), —C(aminoalkylene), —C(SMe) or —C[C(O)Me]. 
     
     
         28 . The compound according to  claim 21 , wherein A 2  is —CH, A 3  is —CR 7  and —CR 7 — is —C(OH), —C(CN), —C(F), —C(Cl), —C(OMe), —C(Me), —C(Et), —C(CHF 2 ) or —C(CF 3 ). 
     
     
         29 . The compound according to  claim 21 , wherein R 3 , R 4  and R 5  independently are —H. 
     
     
         30 . The compound according to  claim 21 , wherein R 3  is —H and R 4  and R 5  independently are chlorine, fluorine, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, —CN, —NHR 10  or —O(C 1 -C 8 )alkylNHR 10 . 
     
     
         31 . The compound according to  claim 21 , wherein R 6a  is —H. 
     
     
         32 . The compound according to  claim 29 , wherein R 10  is —H, —C(O)alkyl or —C(O)cycloalkyl. 
     
     
         33 . The compound according to  claim 21 , wherein R 3  is —H and R 4  and R 5  together with the respective carbon atoms to which they are attached form a fused cycloalkyl, heterocyclyl, or heteroaryl ring. 
     
     
         34 . The compound according to  claim 31 , wherein the heterocyclyl ring is morpholine, pyrrolidine or pyrrolidin-2-one. 
     
     
         35 . The compound according to  claim 31 , wherein the heteroaryl ring is imidazole, thiazole, thiophene, pyrazole, N-methylpyrazole or pyridine. 
     
     
         36 . The compound according to  claim 21 , selected from 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof. 
     
     
         37 . A pharmaceutical composition comprising (i) a therapeutically effective amount of at least one compound according to claim  1  or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof; (ii) in combination with a pharmaceutically acceptable carrier, diluent or excipient. 
     
     
         38 . A method for attenuating or inhibiting the activity of Mnk in at least one cell overexpressing Mnk, comprising contacting the at least one cell with a compound according to claim  1  or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. 
     
     
         39 . The method of  claim 37 , wherein the at least one cell is a colorectal cancer cell, a gastric cancer cell, a bladder cancer cell, an esophageal cancer cell, a head and neck cancer cell, a malignant glioma cell, a glioblastoma cell, a hepatocellular cancer cell, a thyroid cancer cell, a lung cancer cell, a leukemia cell, a B-cell lymphoma cell, a T-cell lymphoma cell, a hairy cell lymphoma cell, a non-small cell cancer cell, a small-cell lung cancer cell, a Hodgkin's lymphoma cell, a non-Hodgkin's lymphoma cell, a Burkitt's lymphoma cell, a pancreatic cancer cell, a pancreatic carcinoma cell, a melanoma cell, a multiple myeloma cell, a myelodysplastic syndrome, a brain cancer cell, a CNS cancer cell, a renal cell carcinoma cell, a prostate cancer cell, a castration-resistant prostate cancer cell, a cervical cancer cell, an urothelial cancer cell, an ovarian cancer cell, a breast cancer cell, or a triple-negative breast cancer cell. 
     
     
         40 . The method of  claim 37 , wherein the at least one cell is a cancer cell.